The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
BackgroundOfatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591056407887872 |
|---|---|
| author | Yue Zhou Yutong Wu Xiao Zhao Lingxu Xu Mingguang Sun Zhaoyou Meng |
| author_facet | Yue Zhou Yutong Wu Xiao Zhao Lingxu Xu Mingguang Sun Zhaoyou Meng |
| author_sort | Yue Zhou |
| collection | DOAJ |
| description | BackgroundOfatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical application of Ofatumumab, comprehending its safety profile within actual healthcare environments is of considerable importance.MethodsThis study compiled a dataset derived from the FAERS database, which included real-world safety data on Ofatumumab from Q4 2009 to Q2 2024. We applied four distinct methodologies, including ROR, PRR, MGPS, and BCPNN, to perform a disproportionality analysis of adverse events (AEs) associated with Ofatumumab. Furthermore, we utilized the Weibull distribution model to estimate the temporal risk pattern of AEs.ResultsThe investigation incorporated a total of 24,468 case reports pertaining to AEs associated with Ofatumumab. The commonly observed AEs encompass Fatigue, Headache, Chills, Pyrexia, Pain, Nausea, Nasopharyngitis, Vomiting, Urinary tract infection, and Pneumonia. Additionally, we identified potential AEs not specified on the drug label, such as Asthenia, Hypoesthesia, Dizziness, Malaise, Injection site pain, Paresthesia, and Diarrhea.ConclusionsThis investigation has identified several AEs associated with Ofatumumab and revealed previously unacknowledged potential adverse reaction signals. Healthcare providers can refer to these adverse reaction signals to more comprehensively consider the possible conditions that patients may present with during actual clinical practice. |
| format | Article |
| id | doaj-art-c04bc09cc6f14b17bc8aa018d8b22f4d |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-c04bc09cc6f14b17bc8aa018d8b22f4d2025-01-23T05:10:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15157301515730The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting systemYue ZhouYutong WuXiao ZhaoLingxu XuMingguang SunZhaoyou MengBackgroundOfatumumab is a humanized monoclonal antibody that targets CD20-positive B cells. It was approved by the FDA in 2020 for the treatment of relapsing multiple sclerosis (RMS) in adult patients, and in 2009 for the treatment of Chronic Lymphocytic Leukemia (CLL). With the escalating clinical application of Ofatumumab, comprehending its safety profile within actual healthcare environments is of considerable importance.MethodsThis study compiled a dataset derived from the FAERS database, which included real-world safety data on Ofatumumab from Q4 2009 to Q2 2024. We applied four distinct methodologies, including ROR, PRR, MGPS, and BCPNN, to perform a disproportionality analysis of adverse events (AEs) associated with Ofatumumab. Furthermore, we utilized the Weibull distribution model to estimate the temporal risk pattern of AEs.ResultsThe investigation incorporated a total of 24,468 case reports pertaining to AEs associated with Ofatumumab. The commonly observed AEs encompass Fatigue, Headache, Chills, Pyrexia, Pain, Nausea, Nasopharyngitis, Vomiting, Urinary tract infection, and Pneumonia. Additionally, we identified potential AEs not specified on the drug label, such as Asthenia, Hypoesthesia, Dizziness, Malaise, Injection site pain, Paresthesia, and Diarrhea.ConclusionsThis investigation has identified several AEs associated with Ofatumumab and revealed previously unacknowledged potential adverse reaction signals. Healthcare providers can refer to these adverse reaction signals to more comprehensively consider the possible conditions that patients may present with during actual clinical practice.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/fullofatumumabFAERSMSCLLpharmacovigilanceadverse events |
| spellingShingle | Yue Zhou Yutong Wu Xiao Zhao Lingxu Xu Mingguang Sun Zhaoyou Meng The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system Frontiers in Immunology ofatumumab FAERS MS CLL pharmacovigilance adverse events |
| title | The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system |
| title_full | The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system |
| title_fullStr | The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system |
| title_full_unstemmed | The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system |
| title_short | The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system |
| title_sort | real world safety of ofatumumab a pharmacovigilance analysis based on the fda adverse event reporting system |
| topic | ofatumumab FAERS MS CLL pharmacovigilance adverse events |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1515730/full |
| work_keys_str_mv | AT yuezhou therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT yutongwu therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT xiaozhao therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT lingxuxu therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT mingguangsun therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT zhaoyoumeng therealworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT yuezhou realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT yutongwu realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT xiaozhao realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT lingxuxu realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT mingguangsun realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem AT zhaoyoumeng realworldsafetyofofatumumabapharmacovigilanceanalysisbasedonthefdaadverseeventreportingsystem |